<DOC>
	<DOCNO>NCT01012973</DOCNO>
	<brief_summary>To determine efficacy vascular endothelial growth factor ( VEGF ) Trap-Eye inject eye vision function subject macular edema consequence central retinal vein occlusion</brief_summary>
	<brief_title>Vascular Endothelial Growth Factor ( VEGF ) Trap-Eye : Investigation Efficacy Safety Central Retinal Vein Occlusion ( CRVO )</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Centerinvolved macular edema secondary central retinal vein occlusion ( CRVO ) longer 9 month mean central subfield thickness ≥ 250 μm optical coherence tomography ( OCT ) Adults ≥ 18 year Early treatment diabetic retinopathy study ( ETDRS ) best correct visual acuity ( BCVA ) 20/40 20/320 ( 73 24 letter ) study eye Any prior treatment antiVEGF agent study eye ( Pegaptanib sodium , anecortave acetate , bevacizumab , ranibizumab , etc . ) previous administration systemic antiangiogenic medication Prior panretinal laser photocoagulation macular laser photocoagulation study eye CRVO disease duration &gt; 9 month date diagnosis Previous use intraocular corticosteroid study eye use periocular corticosteroid study eye within 3 month prior Day 1 Iris neovascularization , vitreous hemorrhage , traction retinal detachment , preretinal fibrosis involve macula either study eye fellow eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Macular Edema</keyword>
	<keyword>Central Retinal Vein Occlusion</keyword>
	<keyword>CRVO</keyword>
	<keyword>VEGF Trap-Eye</keyword>
	<keyword>best-corrected visual acuity</keyword>
</DOC>